HypertensionNCT07025928
Salt Intake and Blood Pressure Control in Adults With Essential Hypertension
A study testing Decreased Salt High Potassium Tool (DSHP Tool) in people with Hypertension, run by Sun Jingfeng at 1 site in Singapore.
Trial summary
The goal of this study is to explore the barriers and facilitators to adopting a reduced dietary salt and increased potassium intake among adults with essential hypertension in Singapore, and to evaluate the feasibility and preliminary effectiveness of a newly developed educational tool-Decreased Salt High Potassium… Read more about this study
- Who is it for?
- Ages 21 years and older
- Conditions the study is for
- Hypertension
- What is being tested?
- Decreased Salt High Potassium Tool (DSHP Tool)
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 190 participants
- Where
- 1 siteSingapore
- Study dates
- 1 Apr 2026to 31 Jul 2030
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Participants who are 21 years old and above.
- Participants who self-reports to have hypertension for at least six months and/ or taking at least one type of antihypertensive medication daily for at least six months
- Able to read English
- HCPs who had prior experience in advising patients on dietary salt reduction
- HCPs who self-reported to have ever treated patients with hypertension
Who cannot join
- Participants with type 1/ type 2 or secondary diabetes mellitus
- Participants with CKD stage 3B and above
- Participants with serum potassium of above 4.5mmol/L (on the latest blood test)
- Participants with serum sodium of less than 135 mmol/L (on the latest blood test)
- Participants who are on daily potassium chloride
- Participants who are on diuretics (thiazide or thiazide like diuretics)
Show all 13Show fewer
- Participants who are pregnant
- Participants who had been diagnosed with any terminal illnesses, visually impaired, disability or mental health related illnesses (visually impaired refers to individuals who self-report to have difficulty reading the wordings on the patient consent form, even with the use of visual aids)
- Participants who are not clinically stable (Clinically stable patients are defined in this study as:
- Has clinic BP 100-160/60-100 mmHg, Heart Rate (HR) 60-100 bpm
- No recent hospitalizations (within the last 3 months) due to hypertensive emergencies, strokes, myocardial infarctions or other acute cardiovascular events
- No recent symptoms such as severe dizziness, fainting, or chest pain) *Participants who are on PRN potassium supplements is not an exclusion criteria
- -nil
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Singapore1 site, 1 recruiting
- Recruiting
Jingfeng Sun
Singapore, Singapore, 820681
Jingfeng Sun, 91390121, sun.jingfeng@singhealth.com.sg
About this study
The goal of this study is to explore the barriers and facilitators to adopting a reduced dietary salt and increased potassium intake among adults with essential hypertension in Singapore, and to evaluate the feasibility and preliminary effectiveness of a newly developed educational tool-Decreased Salt High Potassium (DSHP) Diet Tool-in reducing dietary sodium intake and increasing potassium intake.
This three-part study will involve adults aged 21 years and above, with a self-reported diagnosis of hypertension for at least six months and/or currently taking antihypertensive medication. Participants will be recruited from two SingHealth Polyclinics (Punggol Polyclinic and Pasir Ris Polyclinic). Healthcare providers (HCPs) working at these clinics who have experience in managing patients with hypertension and in educating patients on reducing dietary sodium intake will also be recruited.
Read more
The main questions this study aims to answer are:
- What are the perceived barriers and facilitators for patients with hypertension to reduce dietary sodium and increase potassium intake?
- What are the perceived barriers and facilitators experienced by healthcare providers in educating patients about sodium reduction and potassium intake?
- Is the DSHP Diet Tool feasible and effective in reducing dietary sodium intake and increasing potassium intake among patients with hypertension?
Participants in the intervention group will be provided DSHP Diet Tool and Decreased Salt High Potassium patient information leaflet (DSHP PIL). Participants in the control group will receive standard care and a patient information leaflet (DSHP PIL). Researchers will compare participants in the intervention group to the control group to determine whether the DSHP tool is effective in reducing dietary sodium and increasing potassium intake in patients with hypertension.
Read the detailed description
Hypertension is a major public health concern globally, contributing to cardiovascular disease and premature mortality. According to the World Health Organization (2023), one in three adults worldwide suffers from hypertension. In Singapore, the 2022 National Population Health Survey reported that over 35% of residents aged 18 to 74 years had hypertension, with nearly 65% of those under medical follow-up exhibiting poor blood pressure control. One of the most significant and modifiable risk factors for hypertension is diet-specifically, excessive sodium (salt) intake and insufficient potassium intake.
Excess sodium elevates blood pressure by causing fluid retention and adversely affecting vascular function. Conversely, potassium intake helps regulate blood pressure through mechanisms like promoting sodium excretion and reducing vascular resistance. The benefits of dietary sodium reduction and increasing potassium intake are well-established in both clinical trials and population studies, particularly in individuals with hypertension.
Despite this, Singaporeans continue to consume well above the recommended daily intake for sodium and below the optimal levels for potassium. The average sodium intake is approximately 3,620 mg/day (exceeding the WHO recommendation of 2,000 mg/day), while potassium intake averages 2,500 mg/day (below the recommended 3,510 mg/day). Public health initiatives like the "War on Salt" campaign (launched in 2011) have had limited long-term success in addressing these dietary gaps.
Previous studies in Singapore and neighboring countries have identified significant gaps in knowledge, attitudes, and behaviors related to dietary sodium and potassium. However, there has been limited research focused on practical, context-specific educational interventions aimed at improving dietary behaviors related to salt and potassium intake, especially within the hypertensive population in the primary care setting.
Study Objectives and Hypothesis This study is designed in three parts to systematically develop, refine, and evaluate a novel educational tool-the Decreased Salt High Potassium (DSHP) Diet Tool-for hypertensive patients. The tool aims to support patients in reducing dietary sodium and increasing potassium intake, thereby improving blood pressure control and overall cardiovascular risk profiles.
Primary Hypothesis: A targeted educational tool, developed based on patient and healthcare provider input, will be feasible and effective in supporting reductions in sodium intake and increases in potassium intake among hypertensive patients, leading to improved blood pressure outcomes.
Objectives:
Part 1:
- Identify perceived barriers, facilitators, and attitudes towards reduced sodium and increased potassium diets among hypertensive patients.
- Understand healthcare providers' (HCPs) perspectives on the barriers in educating patients about reducing sodium intake and increasing potassium intake.
Part 2:
- Develop a prototype DSHP Diet Tool based on findings from Part 1.
- Alpha-test the tool with both patients and HCPs to assess usability and acceptability.
- Refine the tool through multiple feedback cycles using qualitative interviews and usability surveys (System Usability Scale - SUS).
Part 3:
- Conduct a pilot randomized controlled trial (RCT) to evaluate the feasibility, usability, and preliminary effectiveness of the DSHP Diet Tool in real-world clinical settings.
Study Design Overview
The study will be conducted in three distinct but interrelated parts:
Part 1: Qualitative study
Design: Qualitative study using in-depth interviews and/or focus group discussions guided by the Theoretical Domains Framework (TDF). Population: 40 hypertensive patients and 20 healthcare providers from two SingHealth Polyclinics (Punggol and Pasir Ris). Sampling: Purposive sampling to ensure diversity in age, gender, ethnicity in patients Data Collection:
- Audio-recorded, semi-structured interviews will be carried out Data Analysis: Thematic analysis using the TDF as a guiding framework. Coding will be conducted independently by multiple researchers to ensure reliability. Data collection will continue until saturation is achieved.
Part 2: Development and Alpha Testing of DSHP Diet Tool
Design: Mixed-methods developmental study. Tool Development: Content developed using findings from Part 1 and validated through collaboration with dietitians, nurses, content experts, and HCPs. Components include:
- General education on sodium and potassium.
- Sodium intake calculator and tracker.
- Food lists and risk matrix.
- Behavior change strategies and goal setting.
- Progress tracking and support resources.
Alpha Testing:
- 20 hypertensive patients and 20 HCPs will test the tool over four iterative cycles (5 patients and 5 HCPs per round).
- Participants will use the DSHP Tool for two weeks.
- Feedback collected via System Usability Scale (SUS) and semi-structured interviews.
- DSHP Tool will be revised based on feedback from each cycle.
Outcome Measures:
- SUS scores (target usability score ≥ 68).
- Feedback on usability and feasibility of the DSHP Tool
Part 3: Pilot Randomized Controlled Trial (RCT) Design: Parallel, two-arm, 1:1 allocation pilot RCT with mixed-method evaluation. Sites: SingHealth Polyclinic - Punggol and SingHealth Polyclinic - Pasir Ris. Sample Size: 80 patients with hypertension (40 per arm), with 25% over-recruitment to account for attrition. Randomization: Using sealed, sequentially numbered opaque envelopes (SNOEs) prepared by an independent researcher. Duration: 24-week intervention period.
Arms:
- Intervention Group: DSHP Tool + Patient Information Leaflet (PIL).
- Control Group: Standard care + PIL.
Assessments (Baseline and 24 weeks):
- Blood pressure (systolic/diastolic)
- Body weight and height
- Serum sodium, potassium, creatinine
- 24-hour urinary sodium and potassium
- Salt literacy and DASH adherence scores
Qualitative Component: At the end of the RCT, a subset of patients from the intervention group will participate in interviews to provide in-depth feedback on acceptability, usability of the DSHP Tool.
Statistical Methods
Quantitative Analysis:
- Independent t-tests or Wilcoxon rank-sum tests for group comparisons.
- Paired t-tests or Wilcoxon signed-rank tests for within-group comparisons.
- Categorical variables analyzed using chi-square tests.
- Intention-to-treat (ITT) principles will be used.
- Missing data managed via multiple imputation or last observation carried forward.
Qualitative Analysis:
- Framework analysis based on TDF.
- Coding verified by multiple investigators.
- Triangulation with quantitative data for integrated interpretation.
Ethical Considerations and Safety
- The study has obtained approval from the SingHealth Centralised Institutional Review Board (CIRB).
- Written informed consent will be obtained from all participants.
- Participants may withdraw at any time without penalty.
- All data will be de-identified and stored securely.
- Risks include potential discomfort during interviews or dietary changes, and rare risks such as hyperkalemia or hyponatremia. Patients at risk of hyperkalemia or hyponatremia are excluded from participation.
Expected Impact and Significance
This study aims to address critical gaps in dietary management of hypertension in Singapore by:
- Developing a practical, theory-informed, user-centered dietary tool.
- Empowering patients to self-manage their hypertension through improved dietary habits.
- Supporting HCPs with an effective educational resource.
- Conditions
- Hypertension
- Being tested
- Decreased Salt High Potassium Tool (DSHP Tool)
- Keywords
- Hypertension, sodium reduction, increased potassium intake, reduced salt, blood pressure control, primary care, Singapore, educational intervention
- Medical subject headings
- Hypertension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Decreased Salt High Potassium Tool (DSHP Tool)Behavioural
Participants in this arm will receive standard hypertension care and the Decreased Salt High Potassium (DSHP)Tool for 24 weeks. The DSHP Tool is an educational resource which includes a sodium intake calculator and tracker, potassium-rich food lists, risk matrix visuals, goal-setting modules tailored to the Singaporean diet. Participants will also receive the DSHP Patient Information Leaflet (PIL) .
| Study group | Role | What they receive |
|---|---|---|
| DSHP Diet Tool and DSHP Patient information leaflet | Experimental | Participants in this arm will receive standard hypertension care along with access to the Decreased Salt High Potassium (DSHP) Diet Tool for 24 weeks and DSHP Patient information leaflet. The DSHP Tool is a patient-centered educational resource developed to support sodium reduction and increase potassium intake through practical strategies, goal setting, and food guidance. Participants will also receive the DSHP Patient Information Leaflet (PIL). Patients will be guided on how to use the tool by a study coordinator. Clinical and dietary assessments will be conducted at baseline and at the end of the intervention. Receives: Behavioral: Decreased Salt High Potassium Tool (DSHP Tool) |
| Standard Care + DSHP Patient Information Leaflet | No intervention | Participants in this arm will receive standard hypertension care as provided at SingHealth Polyclinics, along with the DSHP Patient Information Leaflet (PIL). The PIL provides written guidance on reducing sodium and increasing potassium intake. No access to the DSHP Tool will be provided in this arm. Participants will undergo the same clinical and dietary assessments as the intervention group at baseline and after 24 weeks. |
What is being measured
The primary outcome is the main question the study is designed to answer.
24 hour Urinary Sodium level
24 hour urinary sodium level will be assessed at baseline and at the end of the intervention
Measured: At baseline and at the end of the intervention (24 weeks)
24 hour urinary potassium level
24 hour urinary potassium level will be measured at baseline and at the end of intervention (24 weeks)
Measured: at baseline and at the end of intervention (24 weeks)
Secondary outcomes (4)
Blood pressure
Blood pressure will be assessed at baseline and at the end of the intervention (24 weeks)
Measured: at baseline and at the end of intervention (24 weeks)
Body mass index
Body mass index will be measured at baseline and at the end of 24 weeks
Measured: at baseline and at the end of 24 weeks
Salt literacy scale
Salt literacy scale will be measured at baseline and at the end of intervention (24 weeks). Changes in salt literacy will be assessed using a validated Health Literacy Scale for Low Salt Consumption, which measures participants' knowledge, attitudes, and behaviors related to salt intake. The salt literacy scale has a possible score ranging from 0 to 98, with a higher score indicating higher health literacy related to low salt intake.
Measured: At baseline and at the end of intervention (24 weeks)
DASH score
DASH score will be measured at baseline and at the end of intervention (24 weeks). Adherence to the DASH (Dietary Approaches to Stop Hypertension) diet will be evaluated using the DASH score questionnaire, reflecting overall dietary behavior in relation to sodium and potassium intake. Minimum Score: 0, Maximum Score: 63 , with higher score indicating better adherence to the DASH diet
Measured: at baseline and at the end of intervention (24 weeks)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Jun 2025
- Study start1 Apr 2026 (estimated)
- Primary completion31 Jul 2030 (estimated)
- Study completion31 Jul 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (12)Papers the sponsor has linked to this study.
- Other trials for HypertensionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 190 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sun Jingfeng
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Sun Jingfeng, SingHealth Polyclinics
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07025928
- Sponsor's protocol ID
- 2025-0006
- Other IDs
- SHP-CG-CRGNov24-A05
- Status last verified
- Apr 2026
- First submitted
- 3 Apr 2025
- Last updated
- 30 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data (IPD) will not be shared due to concerns about maintaining participant confidentiality and data privacy. As the study involves sensitive health information and is conducted in a clinical setting, data sharing could increase the risk of re-identification despite de-identification measures. Additionally, participants were not consented for public data sharing at the time of enrollment.
Publications
Silva-Santos T, Moreira P, Rodrigues M, Padrao P, Pinho O, Norton P, Ndrio A, Goncalves C. Interventions That Successfully Reduced Adults Salt Intake-A Systematic Review. Nutrients. 2021 Dec 21;14(1):6. doi: 10.3390/nu14010006.
PubMed 35010883Cheong SM, Ambak R, Othman F, He FJ, Salleh R, Mohd Sallehudin S, Palaniveloo L, Ganapathy SS. Knowledge, perception, and practice related to sodium intake among Malaysian adults: findings from the Malaysian Community Salt Study (MyCoSS). J Health Popul Nutr. 2021 May 31;40(Suppl 1):5. doi: 10.1186/s41043-021-00231-4.
PubMed 34059162Chan CMJ, Dickens BSL, Chong MF. Understanding knowledge, attitudes and behaviours related to dietary sodium intake in a multi-ethnic population in Singapore. Public Health Nutr. 2023 Dec;26(12):2802-2814. doi: 10.1017/S1368980023002422. Epub 2023 Nov 3.
PubMed 37921207Aaron KJ, Sanders PW. Role of dietary salt and potassium intake in cardiovascular health and disease: a review of the evidence. Mayo Clin Proc. 2013 Sep;88(9):987-95. doi: 10.1016/j.mayocp.2013.06.005.
PubMed 24001491Ekmekcioglu C, Elmadfa I, Meyer AL, Moeslinger T. The role of dietary potassium in hypertension and diabetes. J Physiol Biochem. 2016 Mar;72(1):93-106. doi: 10.1007/s13105-015-0449-1. Epub 2015 Dec 3.
PubMed 26634368Koh J, Ang G, Tan KB, Chen C. The social cost of high sodium diet in Singapore. Br J Nutr. 2023 May 14;129(9):1598-1606. doi: 10.1017/S0007114522001568. Epub 2022 May 26.
PubMed 35614498Bibbins-Domingo K, Chertow GM, Coxson PG, Moran A, Lightwood JM, Pletcher MJ, Goldman L. Projected effect of dietary salt reductions on future cardiovascular disease. N Engl J Med. 2010 Feb 18;362(7):590-9. doi: 10.1056/NEJMoa0907355. Epub 2010 Jan 20.
PubMed 20089957Pimenta E, Gaddam KK, Oparil S, Aban I, Husain S, Dell'Italia LJ, Calhoun DA. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension. 2009 Sep;54(3):475-81. doi: 10.1161/HYPERTENSIONAHA.109.131235. Epub 2009 Jul 20.
PubMed 19620517He FJ, Li J, Macgregor GA. Effect of longer-term modest salt reduction on blood pressure. Cochrane Database Syst Rev. 2013 Apr 30;2013(4):CD004937. doi: 10.1002/14651858.CD004937.pub2.
PubMed 23633321Grillo A, Salvi L, Coruzzi P, Salvi P, Parati G. Sodium Intake and Hypertension. Nutrients. 2019 Aug 21;11(9):1970. doi: 10.3390/nu11091970.
PubMed 31438636Adrogue HJ, Madias NE. Sodium and potassium in the pathogenesis of hypertension. N Engl J Med. 2007 May 10;356(19):1966-78. doi: 10.1056/NEJMra064486. No abstract available.
PubMed 17494929Vaduganathan M, Mensah GA, Turco JV, Fuster V, Roth GA. The Global Burden of Cardiovascular Diseases and Risk: A Compass for Future Health. J Am Coll Cardiol. 2022 Dec 20;80(25):2361-2371. doi: 10.1016/j.jacc.2022.11.005. Epub 2022 Nov 9. No abstract available.
PubMed 36368511
Study at a glance
From the registry record, last updated by the sponsor on 30 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Salt Intake and Blood Pressure Control in Adults With Essential Hypertension
- ClinicalTrials.gov ID
- NCT07025928
- Acronym / sponsor ID
- 2025-0006
- Conditions
- Hypertension
- Keywords
- Hypertension, sodium reduction, increased potassium intake, reduced salt, blood pressure control, primary care, Singapore, educational intervention
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 190 participants (estimated)
- Lead sponsor
- Sun JingfengUniversity, hospital or other
- Study start
- 1 Apr 2026 (estimated)
- Primary completion
- 31 Jul 2030 (estimated)
- Study completion
- 31 Jul 2030 (estimated)
- First posted
- 18 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this study is to explore the barriers and facilitators to adopting a reduced dietary salt and increased potassium intake among adults with essential hypertension in Singapore, and to evaluate the feasibility and preliminary effectiveness of a newly developed educational tool-Decreased Salt High Potassium (DSHP) Diet Tool-in reducing dietary sodium intake and increasing potassium intake.
This three-part study will involve adults aged 21 years and above, with a self-reported diagnosis of hypertension for at least six months and/or currently taking antihypertensive medication. Participants will be recruited from two SingHealth Polyclinics (Punggol Polyclinic and Pasir Ris Polyclinic). Healthcare providers (HCPs) working at these clinics who have experience in managing patients with hypertension and in educating patients on reducing dietary sodium intake will also be recruited.
The main questions this study aims to answer are:
- What are the perceived barriers and facilitators for patients with hypertension to reduce dietary sodium and increase potassium intake?
- What are the perceived barriers and facilitators experienced by healthcare providers in educating patients about sodium reduction and potassium intake?
- Is the DSHP Diet Tool feasible and effective in reducing dietary sodium intake and increasing potassium intake among patients with hypertension?
Participants in the intervention group will be provided DSHP Diet Tool and Decreased Salt High Potassium patient information leaflet (DSHP PIL). Participants in the control group will receive standard care and a patient information leaflet (DSHP PIL). Researchers will compare participants in the intervention group to the control group to determine whether the DSHP tool is effective in reducing dietary sodium and increasing potassium intake in patients with hypertension.
Detailed description
Hypertension is a major public health concern globally, contributing to cardiovascular disease and premature mortality. According to the World Health Organization (2023), one in three adults worldwide suffers from hypertension. In Singapore, the 2022 National Population Health Survey reported that over 35% of residents aged 18 to 74 years had hypertension, with nearly 65% of those under medical follow-up exhibiting poor blood pressure control. One of the most significant and modifiable risk factors for hypertension is diet-specifically, excessive sodium (salt) intake and insufficient potassium intake.
Excess sodium elevates blood pressure by causing fluid retention and adversely affecting vascular function. Conversely, potassium intake helps regulate blood pressure through mechanisms like promoting sodium excretion and reducing vascular resistance. The benefits of dietary sodium reduction and increasing potassium intake are well-established in both clinical trials and population studies, particularly in individuals with hypertension.
Despite this, Singaporeans continue to consume well above the recommended daily intake for sodium and below the optimal levels for potassium. The average sodium intake is approximately 3,620 mg/day (exceeding the WHO recommendation of 2,000 mg/day), while potassium intake averages 2,500 mg/day (below the recommended 3,510 mg/day). Public health initiatives like the "War on Salt" campaign (launched in 2011) have had limited long-term success in addressing these dietary gaps.
Previous studies in Singapore and neighboring countries have identified significant gaps in knowledge, attitudes, and behaviors related to dietary sodium and potassium. However, there has been limited research focused on practical, context-specific educational interventions aimed at improving dietary behaviors related to salt and potassium intake, especially within the hypertensive population in the primary care setting.
Study Objectives and Hypothesis This study is designed in three parts to systematically develop, refine, and evaluate a novel educational tool-the Decreased Salt High Potassium (DSHP) Diet Tool-for hypertensive patients. The tool aims to support patients in reducing dietary sodium and increasing potassium intake, thereby improving blood pressure control and overall cardiovascular risk profiles.
Primary Hypothesis: A targeted educational tool, developed based on patient and healthcare provider input, will be feasible and effective in supporting reductions in sodium intake and increases in potassium intake among hypertensive patients, leading to improved blood pressure outcomes.
Objectives:
Part 1:
- Identify perceived barriers, facilitators, and attitudes towards reduced sodium and increased potassium diets among hypertensive patients.
- Understand healthcare providers' (HCPs) perspectives on the barriers in educating patients about reducing sodium intake and increasing potassium intake.
Part 2:
- Develop a prototype DSHP Diet Tool based on findings from Part 1.
- Alpha-test the tool with both patients and HCPs to assess usability and acceptability.
- Refine the tool through multiple feedback cycles using qualitative interviews and usability surveys (System Usability Scale - SUS).
Part 3:
- Conduct a pilot randomized controlled trial (RCT) to evaluate the feasibility, usability, and preliminary effectiveness of the DSHP Diet Tool in real-world clinical settings.
Study Design Overview
The study will be conducted in three distinct but interrelated parts:
Part 1: Qualitative study
Design: Qualitative study using in-depth interviews and/or focus group discussions guided by the Theoretical Domains Framework (TDF). Population: 40 hypertensive patients and 20 healthcare providers from two SingHealth Polyclinics (Punggol and Pasir Ris). Sampling: Purposive sampling to ensure diversity in age, gender, ethnicity in patients Data Collection:
- Audio-recorded, semi-structured interviews will be carried out Data Analysis: Thematic analysis using the TDF as a guiding framework. Coding will be conducted independently by multiple researchers to ensure reliability. Data collection will continue until saturation is achieved.
Part 2: Development and Alpha Testing of DSHP Diet Tool
Design: Mixed-methods developmental study. Tool Development: Content developed using findings from Part 1 and validated through collaboration with dietitians, nurses, content experts, and HCPs. Components include:
- General education on sodium and potassium.
- Sodium intake calculator and tracker.
- Food lists and risk matrix.
- Behavior change strategies and goal setting.
- Progress tracking and support resources.
Alpha Testing:
- 20 hypertensive patients and 20 HCPs will test the tool over four iterative cycles (5 patients and 5 HCPs per round).
- Participants will use the DSHP Tool for two weeks.
- Feedback collected via System Usability Scale (SUS) and semi-structured interviews.
- DSHP Tool will be revised based on feedback from each cycle.
Outcome Measures:
- SUS scores (target usability score ≥ 68).
- Feedback on usability and feasibility of the DSHP Tool
Part 3: Pilot Randomized Controlled Trial (RCT) Design: Parallel, two-arm, 1:1 allocation pilot RCT with mixed-method evaluation. Sites: SingHealth Polyclinic - Punggol and SingHealth Polyclinic - Pasir Ris. Sample Size: 80 patients with hypertension (40 per arm), with 25% over-recruitment to account for attrition. Randomization: Using sealed, sequentially numbered opaque envelopes (SNOEs) prepared by an independent researcher. Duration: 24-week intervention period.
Arms:
- Intervention Group: DSHP Tool + Patient Information Leaflet (PIL).
- Control Group: Standard care + PIL.
Assessments (Baseline and 24 weeks):
- Blood pressure (systolic/diastolic)
- Body weight and height
- Serum sodium, potassium, creatinine
- 24-hour urinary sodium and potassium
- Salt literacy and DASH adherence scores
Qualitative Component: At the end of the RCT, a subset of patients from the intervention group will participate in interviews to provide in-depth feedback on acceptability, usability of the DSHP Tool.
Statistical Methods
Quantitative Analysis:
- Independent t-tests or Wilcoxon rank-sum tests for group comparisons.
- Paired t-tests or Wilcoxon signed-rank tests for within-group comparisons.
- Categorical variables analyzed using chi-square tests.
- Intention-to-treat (ITT) principles will be used.
- Missing data managed via multiple imputation or last observation carried forward.
Qualitative Analysis:
- Framework analysis based on TDF.
- Coding verified by multiple investigators.
- Triangulation with quantitative data for integrated interpretation.
Ethical Considerations and Safety
- The study has obtained approval from the SingHealth Centralised Institutional Review Board (CIRB).
- Written informed consent will be obtained from all participants.
- Participants may withdraw at any time without penalty.
- All data will be de-identified and stored securely.
- Risks include potential discomfort during interviews or dietary changes, and rare risks such as hyperkalemia or hyponatremia. Patients at risk of hyperkalemia or hyponatremia are excluded from participation.
Expected Impact and Significance
This study aims to address critical gaps in dietary management of hypertension in Singapore by:
- Developing a practical, theory-informed, user-centered dietary tool.
- Empowering patients to self-manage their hypertension through improved dietary habits.
- Supporting HCPs with an effective educational resource.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| DSHP Diet Tool and DSHP Patient information leaflet | Experimental | Behavioral: Decreased Salt High Potassium Tool (DSHP Tool)Participants in this arm will receive standard hypertension care along with access to the Decreased Salt High Potassium (DSHP) Diet Tool for 24 weeks and DSHP Patient information leaflet. The DSHP Tool is a patient-centered educational resource developed to support sodium reduction and increase potassium intake through practical strategies, goal setting, and food guidance. Participants will also receive the DSHP Patient Information Leaflet (PIL). Patients will be guided on how to use the tool by a study coordinator. Clinical and dietary assessments will be conducted at baseline and at the end of the intervention. |
| Standard Care + DSHP Patient Information Leaflet | No intervention | –Participants in this arm will receive standard hypertension care as provided at SingHealth Polyclinics, along with the DSHP Patient Information Leaflet (PIL). The PIL provides written guidance on reducing sodium and increasing potassium intake. No access to the DSHP Tool will be provided in this arm. Participants will undergo the same clinical and dietary assessments as the intervention group at baseline and after 24 weeks. |
Who may qualify
- Ages
- 21 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Participants who are 21 years old and above.
- Participants who self-reports to have hypertension for at least six months and/ or taking at least one type of antihypertensive medication daily for at least six months
- Able to read English
- HCPs who had prior experience in advising patients on dietary salt reduction
- HCPs who self-reported to have ever treated patients with hypertension
Key exclusion criteria (13 listed)
- Participants with type 1/ type 2 or secondary diabetes mellitus
- Participants with CKD stage 3B and above
- Participants with serum potassium of above 4.5mmol/L (on the latest blood test)
- Participants with serum sodium of less than 135 mmol/L (on the latest blood test)
- Participants who are on daily potassium chloride
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Decreased Salt High Potassium Tool (DSHP Tool)Participants in this arm will receive standard hypertension care and the Decreased Salt High Potassium (DSHP)Tool for 24 weeks. The DSHP Tool is an educational resource which includes a sodium intake calculator and tracker, potassium-rich food lists, risk matrix visuals, goal-setting modules tailored to the Singaporean diet. Participants will also receive the DSHP Patient Information Leaflet (PIL) . | Behavioural | DSHP Diet Tool and DSHP Patient information leaflet |
Primary outcome
24 hour Urinary Sodium level
Time frame: At baseline and at the end of the intervention (24 weeks)
24 hour urinary sodium level will be assessed at baseline and at the end of the intervention
24 hour urinary potassium level
Time frame: at baseline and at the end of intervention (24 weeks)
24 hour urinary potassium level will be measured at baseline and at the end of intervention (24 weeks)
4 secondary outcomes
Blood pressure
Time frame: at baseline and at the end of intervention (24 weeks)
Body mass index
Time frame: at baseline and at the end of 24 weeks
Salt literacy scale
Time frame: At baseline and at the end of intervention (24 weeks)
DASH score
Time frame: at baseline and at the end of intervention (24 weeks)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Apr 2026.
- Background: PubMed 35010883Silva-Santos T, Moreira P, Rodrigues M, Padrao P, Pinho O, Norton P, Ndrio A, Goncalves C. Interventions That Successfully Reduced Adults Salt Intake-A Systematic Review. Nutrients. 2021 Dec 21;14(1):6. doi: 10.3390/nu14010006.
- Background: PubMed 34059162Cheong SM, Ambak R, Othman F, He FJ, Salleh R, Mohd Sallehudin S, Palaniveloo L, Ganapathy SS. Knowledge, perception, and practice related to sodium intake among Malaysian adults: findings from the Malaysian Community Salt Study (MyCoSS). J Health Popul Nutr. 2021 May 31;40(Suppl 1):5. doi: 10.1186/s41043-021-00231-4.
- Background: PubMed 37921207Chan CMJ, Dickens BSL, Chong MF. Understanding knowledge, attitudes and behaviours related to dietary sodium intake in a multi-ethnic population in Singapore. Public Health Nutr. 2023 Dec;26(12):2802-2814. doi: 10.1017/S1368980023002422. Epub 2023 Nov 3.
- Background: PubMed 24001491Aaron KJ, Sanders PW. Role of dietary salt and potassium intake in cardiovascular health and disease: a review of the evidence. Mayo Clin Proc. 2013 Sep;88(9):987-95. doi: 10.1016/j.mayocp.2013.06.005.
- Background: PubMed 26634368Ekmekcioglu C, Elmadfa I, Meyer AL, Moeslinger T. The role of dietary potassium in hypertension and diabetes. J Physiol Biochem. 2016 Mar;72(1):93-106. doi: 10.1007/s13105-015-0449-1. Epub 2015 Dec 3.
- Background: PubMed 35614498Koh J, Ang G, Tan KB, Chen C. The social cost of high sodium diet in Singapore. Br J Nutr. 2023 May 14;129(9):1598-1606. doi: 10.1017/S0007114522001568. Epub 2022 May 26.
- Background: PubMed 20089957Bibbins-Domingo K, Chertow GM, Coxson PG, Moran A, Lightwood JM, Pletcher MJ, Goldman L. Projected effect of dietary salt reductions on future cardiovascular disease. N Engl J Med. 2010 Feb 18;362(7):590-9. doi: 10.1056/NEJMoa0907355. Epub 2010 Jan 20.
- Background: PubMed 19620517Pimenta E, Gaddam KK, Oparil S, Aban I, Husain S, Dell'Italia LJ, Calhoun DA. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension. 2009 Sep;54(3):475-81. doi: 10.1161/HYPERTENSIONAHA.109.131235. Epub 2009 Jul 20.
- Background: PubMed 23633321He FJ, Li J, Macgregor GA. Effect of longer-term modest salt reduction on blood pressure. Cochrane Database Syst Rev. 2013 Apr 30;2013(4):CD004937. doi: 10.1002/14651858.CD004937.pub2.
- Background: PubMed 31438636Grillo A, Salvi L, Coruzzi P, Salvi P, Parati G. Sodium Intake and Hypertension. Nutrients. 2019 Aug 21;11(9):1970. doi: 10.3390/nu11091970.
- Background: PubMed 17494929Adrogue HJ, Madias NE. Sodium and potassium in the pathogenesis of hypertension. N Engl J Med. 2007 May 10;356(19):1966-78. doi: 10.1056/NEJMra064486. No abstract available.
- Background: PubMed 36368511Vaduganathan M, Mensah GA, Turco JV, Fuster V, Roth GA. The Global Burden of Cardiovascular Diseases and Risk: A Compass for Future Health. J Am Coll Cardiol. 2022 Dec 20;80(25):2361-2371. doi: 10.1016/j.jacc.2022.11.005. Epub 2022 Nov 9. No abstract available.
- Individual participant dataSharing planned: No. Individual participant data (IPD) will not be shared due to concerns about maintaining participant confidentiality and data privacy. As the study involves sensitive health information and is conducted in a clinical setting, data sharing could increase the risk of re-identification despite de-identification measures. Additionally, participants were not consented for public data sharing at the time of enrollment.
Related trials for Hypertension
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Enrolling by invitation
Testing Implementation Strategies to Support Clinic Fidelity to an Outpatient Hypertension Bundle
Pregnancy Related, Hypertension
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Decreased Salt High Potassium Tool (DSHP Tool) in people with Hypertension, run by Sun Jingfeng at 1 site in Singapore.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 30 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact SUN JINGFENG, Masters in Medicine(Fam Med) (+6591390121, jingfengsun88@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
24 hour Urinary Sodium level (time frame: At baseline and at the end of the intervention (24 weeks)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07025928, which also lists 12 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Apr 2026.